Quantum Biopharma (QNTM) Total Non-Current Liabilities (2018 - 2026)
Quantum Biopharma recorded quarterly Total Non-Current Liabilities of $11.0 million in Q1 2026, up 82.03% quarter-over-quarter from $6.1 million in Q4 2025, and up 46.97% year-over-year from $7.5 million in Q1 2025.
Quantum Biopharma's Total Non-Current Liabilities history runs 9 years deep, the most recent figure standing at $11.0 million for Q1 2026.
- In Q1 2026, Total Non-Current Liabilities rose 46.97% year-over-year to $11.0 million; the TTM figure through Mar 2026 stood at $11.0 million (up 46.97% YoY), while the FY2025 annual figure was $6.1 million, changed N/A from the prior year.
- Total Non-Current Liabilities came in at $11.0 million for Q1 2026 at Quantum Biopharma, up from $6.1 million in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $11.0 million in Q1 2026 to a low of -$522884.0 in Q1 2022.
- A 5-year average of $3.1 million and a median of $1.9 million in 2022 frame the typical range for Total Non-Current Liabilities.
- Across the five-year window, Total Non-Current Liabilities plunged 98.97% in 2022 and jumped 4223.27% in 2024, its largest moves.
- Quantum Biopharma's Total Non-Current Liabilities stood at $38004.0 in 2022, then slumped by 443.08% to -$130383.0 in 2023, then surged by 2923.19% to $3.7 million in 2024, then jumped by 64.58% to $6.1 million in 2025, then surged by 82.03% to $11.0 million in 2026.
- According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $11.0 million, $6.1 million, and $6.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 11.03 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 42,980.09 |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 95.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 110.28 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 5.87 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 7.32 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 4.05 Bn |
| 10 | Revolution Medicines | 32.39 Bn | 32.39 Bn | - | 746.94 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 11.03 Mn |
| Dec 31, 2025 | 6.06 Mn |
| Sep 30, 2025 | 6.65 Mn |
| Jun 30, 2025 | 5.49 Mn |
| Mar 31, 2025 | 7.50 Mn |
| Sep 30, 2024 | 3.68 Mn |
| Jun 30, 2024 | 5.04 Mn |
| Sep 30, 2023 | -130,383.00 |
| Jun 30, 2023 | -122,351.00 |
| Mar 31, 2023 | -450,544.00 |
| Dec 31, 2022 | 38,004.00 |
| Sep 30, 2022 | -388,481.00 |
| Jun 30, 2022 | -425,620.00 |
| Mar 31, 2022 | -522,884.00 |
| Dec 31, 2021 | 3.69 Mn |
| Sep 30, 2021 | -1.43 Mn |
| Jun 30, 2021 | -1.71 Mn |
| Mar 31, 2021 | -2.00 Mn |
| Dec 31, 2020 | 689,664.00 |
| Sep 30, 2020 | -2.61 Mn |
| Dec 31, 2019 | 2.64 Mn |
| Dec 31, 2018 | -2.04 Mn |